EURneffy 1 mg will be the first and only needle-free adrenaline available to younger children in the European Union ARS Pharma’s partner, ALK-Abelló A/S, who owns the rights to market EURneffy in the ...
SAN DIEGO, March 05, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves ...
The availability of neffy 1 mg extends protection to younger, school-aged children—who make up nearly 23% of people needing epinephrine Visit neffy.com for savings and support programs and pay as ...
(RTTNews) - ARS Pharmaceuticals Inc. (SPRY) announced that the U.S. Food and Drug Administration has approved neffy 1 mg (epinephrine nasal spray) for the treatment of Type I Allergic Reactions, ...
SAN DIEGO, Feb. 02, 2026 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect ...
neffy 1 mg is the first and only needle-free epinephrine treatment approved for younger children “The availability of a needle-free epinephrine option for children is a breakthrough in the treatment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results